KPC Co., Ltd., founded in 1951, is a well-known trademark and listed company in Yunnan Province, leading natural plant medicine products, focusing on pharmaceutical/chemical drugs and pharmaceutical R&D, production, sales, commercial wholesale and international marketing as one of the pharmaceutical enterprises
KPC Co., Ltd. (KPC 600422 SH) was established in March 1951 and listed on the Shanghai Stock Exchange in December 2000. The company has profound professional pharmaceutical experience, and is a national key high-tech enterprise and one of the top 100 enterprises in China's pharmaceutical industry. Its own brands such as Luotai ®, Artemedine® ®, Artem,® Arco®, etc. are well-known at home and abroad.
KPC integrates drug R&D, production, sales, commercial wholesale and international marketing, forming a business structure that focuses on independent natural botanicals, covering traditional Chinese medicine, chemical medicine and pharmaceutical circulation. It owns Kunming Traditional Chinese Medicine Factory Co., Ltd., Kunming Pharmaceutical Group Xuesaitong Pharmaceutical Co., Ltd., Xishuangbanna Banna Pharmaceutical Co., Ltd., Kunming Pharmaceutical Group Pharmaceutical Commercial Co., Ltd., Kunming Baker Norton Pharmaceutical Co., Ltd., Kunming Pharmaceutical Group Nukus Plant Technology Co., Ltd., Kunming Yinnuo Pharmaceutical Technology Co., Ltd., Beijing Huafang Ketai Pharmaceutical Co., Ltd. and other participating holding companies, and has a large-scale manufacturing center, Xuesaitong Pharmaceutical Research Institute and postdoctoral workstation. The "Kunming Pharmaceutical Biomedical Science and Technology Park", which has landed in the National Bio-industry Base of Kunming High-tech Zone, will become a world-leading and domestic first-class large-scale, professional and international biomedical park after completion.
Relying on the abundant plant resources in Yunnan, KPC has successively developed more than 40 new natural plant medicine products with advanced level at home and abroad, such as Artemisia annua series, Panax notoginseng series, Gastrodia series, characteristic Chinese medicine, characteristic ethnic medicine, etc., and has a number of national invention patents, and has a high reputation and reputation in the field of cardiovascular and cerebrovascular, nervous system, malaria and other diseases, and has made positive and significant contributions to the cause of human health.
Outstanding R&D strength, abundant product resources, strong integrated manufacturing system, quality management system in line with international standards, and international marketing team together constitute the irreplaceable core competitive advantage of KPC. In the future, KPC will develop into an international drug provider focusing on cardiovascular and cerebrovascular diseases, focusing on the field of chronic diseases, with the purpose of "Green KPC, Welfare Society", and strive to become a well-known brand and outstanding representative of global cardiovascular and cerebrovascular drugs.
